The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 13, 2022
Filed:
Jun. 24, 2020
Applicant:
Zoetis Services Llc, Parsippany, NJ (US);
Inventors:
Cassius McAllister Tucker, Kalamazoo, MI (US);
John David Haworth, Englewood, CO (US);
Assignee:
Zoetis Services LLC, Parsippany, NJ (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/175 (2006.01); A61K 39/295 (2006.01); A61K 39/00 (2006.01); A61K 39/38 (2006.01); A61K 39/235 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); A61K 39/23 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/235 (2013.01); A61K 39/0225 (2013.01); A61K 39/099 (2013.01); A61K 39/12 (2013.01); A61K 39/155 (2013.01); A61K 39/175 (2013.01); A61K 39/23 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/542 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/10071 (2013.01); C12N 2710/10334 (2013.01); C12N 2750/14034 (2013.01); C12N 2750/14071 (2013.01); C12N 2750/14334 (2013.01); C12N 2760/18034 (2013.01); C12N 2760/18071 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18471 (2013.01); C12N 2770/20022 (2013.01);
Abstract
This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.